好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Responsive Neurostimulation and Focal Cortical Dysplasia: Personalizing Technology to Pathology in Drug-Resistant Epilepsy
Epilepsy/Clinical Neurophysiology (EEG)
P5 - Poster Session 5 (8:00 AM-9:00 AM)
9-003

To evaluate current practice of responsive neurostimulation (RNS) in drug-resistant epilepsy associated with focal cortical dysplasia (DRE-FCD) and the potential of personalizing treatment to improve outcomes.

The RNS System involves two intracranial leads placed at the seizure onset zone(s) where they serve to detect abnormal activity and deliver closed-loop electrical stimulation to reduce seizures. FCDs often result in DRE with unique electrographic and imaging signatures that can be leveraged by RNS.

Our scoping review followed a peer-reviewed search to identify relevant studies on epilepsy and RNS across MEDLINE, Embase, and Web of Science, yielding 674, 1,255, and 579 results, respectively. The final protocol was registered with the Open Science Framework. Data on patient and FCD characteristics, pre-implant imaging/intracranial electroencephalography, seizure outcomes, follow-up duration, and past/concurrent resective/neuromodulation procedures were collected. RNS implantation strategies including target selection, lead type, and programming parameters were recorded. Data for subgroups were analyzed using descriptive and inferential statistics.

75 patients across 24 studies were included. Most FCDs were multifocal, located in frontal followed by temporal regions, lead configuration varied between two depth electrodes (54%), two strip electrodes (31%), and a combination of both (15%). Median seizure reduction was 82% [IQR=50, 90.75] at median follow-up of 12 months [IQR=6, 20], including 3 patients achieving seizure freedom. In 13 patients with concurrent RNS implantation and resection, median seizure reduction was 87% [IQR=70, 95]. The 12 patients with thalamic leads had median seizure reduction of 87% [IQR=13, 87.5]. RNS was found to be effective when used in refractory status epilepticus associated with FCDs.

RNS is a flexible therapy that can be tailored to diverse epilepsies and that effectively reduces seizures in DRE-FCD. Future studies are necessary to determine optimal lead configuration and device programming for DRE-FCD and other lesional epilepsies.

Authors/Disclosures
Vincent Chang, MD
PRESENTER
Dr. Chang has nothing to disclose.
Sandipan Pati (University of Texas Health Science Center at Houston, Mc Govern Medical School) No disclosure on file
Brian Lundstrom, MD, PhD (Mayo Clinic, Neurology Dept) The institution of Dr. Lundstrom has received research support from Medtronic. Dr. Lundstrom has a non-compensated relationship as a Consultant with Cadence Neuroscience that is relevant to AAN interests or activities.
Puck C. Reeders, PhD Dr. Reeders has nothing to disclose.
Vikram Rao, MD (UC San Francisco) Dr. Rao has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Precisis GmbH. Dr. Rao has received personal compensation in the range of $500-$4,999 for serving as a Consultant for iVEAcare. Dr. Rao has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for NeuroPace, Inc.. Dr. Rao has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier. Dr. Rao has stock in Novela Neurotechnologies. Dr. Rao has stock in EnlitenAI. Dr. Rao has stock in Doximity, Inc. Dr. Rao has stock in Theta Neurotech. Dr. Rao has stock in Encephalogix.
Shruti Agashe, MD (Duke University) Dr. Agashe has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Blackrock.